Collaborative Effort of Nonprofits Yields Big Results for Treating High-Risk Neuroblastoma

FOR IMMEDIATE RELEASE

Collaborative Effort of Nonprofits Yields Big Results for Treating High-Risk Neuroblastoma

 

New York, NY, April 3, 2023 The collaborative efforts of eight nonprofit organizations to impact survival rates of children with high-risk neuroblastoma by funding innovative clinical research has just resulted in very promising results. This collaboration, led by Solving Kids’ Cancer, supported the testing of lorlatinib as a targeted drug therapy for treating neuroblastoma tumors that have an alteration in the ALK gene. The clinical trial reported significant responses in relapsed and refractory patients who had disease that was resistant to other therapies.

The findings, recently published in Nature Medicine by senior study author Yael P. Mossé, MD, Professor of Pediatrics in the Cancer Center at Children’s Hospital of Philadelphia (CHOP) and colleagues [link], show that lorlatinib is safe and tolerable and resulted in far more responses than the first-generation ALK inhibitor crizotinib. This work has led to rapidly incorporating this drug in a phase 3 trial for newly diagnosed children with ALK-driven high-risk neuroblastoma, instead of crizotinib. The process took 4.5 years from testing the drug in phase 1 to phase 3, in contrast to 16 years for dinutuximab, the most recent drug approved for first line therapy for neuroblastoma

Neuroblastoma is an aggressive pediatric cancer that develops from early nerve cells, often appearing as a solid tumor in the chest or abdomen. The disease affects very young children, and accounts for up to 10% of childhood cancer deaths. Less than 50% of patients with high-risk disease survive, and researchers continue to identify new ways to treat the disease. With the discovery of subtypes that have mutations that can be targeted, drugs like lorlatinib can “turn off” the ALK mutated driver of the cancer cell and result in dramatic responses and even complete remission.

“We are so pleased and excited about these significant findings,” said Scott Kennedy, Executive Director of Solving Kids’ Cancer, “It validates moving promising therapies earlier in the treatment process before kids relapse. This is a big step in the right direction and illustrates the impact nonprofit collaboration can have with a shared common goal.”

Solving Kids’ Cancer, in partnership with Solving Kids’ Cancer UK, Band of Parents, The Catherine Elizabeth Blair Foundation, Children’s Neuroblastoma Cancer Foundation, The Evan Foundation, Ronan Thompson Foundation, and Wade’s Army also supported sites in London and Paris to give more children access to this important clinical trial.

 

CONTACT:  Kristi McKay

            Solving Kids’ Cancer

            kristi@solvingkidscancer.org

            212-588-6624

 

###

 

About Solving Kids’ Cancer

Solving Kids’ Cancer (SKC) is not just our name, it’s our mission. SKC focuses on improving survival rates for the most aggressive childhood cancers by advancing clinical trials of next-generation treatments and using advocacy to improve uptake of currently available discoveries in a collaborative approach that addresses today’s unmet needs, because every kid deserves to grow up. 

By Kristi McKay December 2, 2024
Ways to Give Back During the Holidays
A man and a little girl are sitting in front of a wooden wall.
By duda November 20, 2024
Ahana’s Story of Strength with High-Risk Neuroblastoma Every day, over 1,000 children worldwide are diagnosed with cancer,1 and for many families, that diagnosis means facing an uncertain future. At just 20 months old, Ahana was diagnosed with a rare and aggressive cancer that had already spread through her small body. Her family’s search for life-saving childhood cancer treatments led them from South Africa to Spain and possibly toward a clinical trial in New York. Ahana’s journey shows the importance of supporting organizations like Solving Kids’ Cancer, which works to find, fund, and advocate for advanced treatments that give hope to families fighting against tough-to-treat rare pediatric cancers.
A poster for 2024 year in review for solving kids ' cancer
November 11, 2024
Advancing Childhood Cancer Research: SKC’s 2024 Milestones
A group of children are holding a sign that says
October 1, 2024
Lace Up for Kids: Your Impact on Childhood Cancer Research At Solving Kids’ Cancer, our mission has always been driven by hope — hope for better treatments, hope for breakthroughs, and most importantly, hope for every child fighting cancer. This year’s Lace Up for Kids campaign was nothing short of inspiring. Together, we’ve raised over $264,000 across the entire campaign, funding innovative childhood cancer research and providing more treatment options for children in need.  From coast to coast, nearly 4,000 participants have stepped up to lace up their gold shoelaces and make a difference. Whether it was through schools, sports teams, or community groups, the show of support has been overwhelming throughout the years. Over 7,823 donations have been made to accelerate new treatments, and the hashtag #CareWearShare has been used 13,864 times, spreading the message far and wide!
A girl is standing in front of a car in a parking lot.
September 2, 2024
Gold Laces for Childhood Cancer Awareness Month: Erin’s Story 
A group of children are standing in a circle with their shoes on the floor.
August 8, 2024
Smithtown Goes Gold for Childhood Cancer Awareness Month!
A poster for lace up for kids with a butterfly on it
August 6, 2024
Childhood Cancer Awareness Month: Lace Up for Kids 2024
A man standing on top of a mountain with the words osteosarcoma survivor to surgeon dr. kurt weiss ' story
August 1, 2024
Osteosarcoma Survivor to Surgeon: Dr. Kurt Weiss’ Story
By Kristi McKay July 4, 2024
A Quick Guide to Your Role as a Parent Advocate 
Jacob 's journey : a childhood cancer survivor 's story
May 10, 2024
Jacob’s Journey: A Childhood Cancer Survivor’s Story Every battle has its heroes, and among the bravest are young children like Jacob Mozer, who faced stage 4 high-risk neuroblastoma when he was barely old enough to walk. Diagnosed at only 16 months old, Jacob’s early years were filled with constant medical appointments and intense treatments. Despite these challenges, today, Jacob is a shining example of the remarkable progress in pediatric oncology. He’s not merely surviving; he’s thriving as a pharmacy resident, driven to give back to the medical community that gave him a second chance at life. During National Cancer Survivors Month this June, we honor and celebrate fighters like Jacob who have battled cancer and emerged stronger. This month also serves to amplify the conversation about pediatric cancer survivorship and push for vital research that continues to save lives. Solving Kids’ Cancer (SKC) plays an essential role in this effort, supporting children like Jacob by funding crucial clinical trials that enhance survival rates and improve the quality of life for those fighting fatal childhood cancers.
More Posts